Posted by Michael Wonder on 11 May 2021
ICER publishes final evidence report and policy recommendations on therapies for multiple myeloma
11 May 2021 - Independent appraisal committee unanimously determined the evidence is adequate to demonstrate that CAR-T treatments ide-cel and cilta-cel both provide a net health benefit when compared to usual care; despite these benefits, for ide-cel, the only CAR-T agent having received FDA approval at this time, a majority of panelists voted that it represents “low” long-term value for money at current pricing.
The Institute for Clinical and Economic Review today released a Final Evidence Report assessing the comparative clinical effectiveness and value of three new treatments targeting the B-cell maturation antigen for heavily pre-treated patients with triple class refractory multiple myeloma who have cycled through numerous previous lines of therapy.
